Page 47 - Development Partnership News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A new Phase III trial has found that zoliflodacin can effectively treat the bacterial infection that has become resistant to nearly every available drug.

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterAnnounced positive...

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resi...

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial...

Antibiotic could turn the tide on drug-resistant form of the infection — if it’s used wisely. Antibiotic could turn the tide on drug-resistant form of the infection — if it’s used wisely.